MedicaidPrior AuthHigh impact
MAb2026063002
Pennsylvania Medicaid (DHS)·PA · Psychiatry, Pediatrics, Pharmacy·Provider Bulletin
Effective date
Jul 6, 2026
We identified it
Jul 1, 2026
Summary
Pennsylvania Medical Assistance (MA) program updated prior authorization requirements for antipsychotic medications effective July 6, 2026. New guidelines require prior auth for non-preferred antipsychotics, pediatric prescriptions (under 18), quantity limits exceeded, and therapeutic duplication. Clinical review now mandates FDA-approved or medically accepted indications, appropriate dosing per FDA labeling or peer-reviewed literature, and for children, comprehensive evaluation, specialist involvement, and baseline metabolic monitoring documentation.
Action Required
By July 6, 2026: (1) Pharmacy billing team must update pharmacy management system to require prior authorization submissions for: non-preferred antipsychotics, antipsychotics prescribed to patients under 18 years, antipsychotics exceeding quantity limits, and therapeutic duplications (atypical-to-atypical or typical-to-typical switches). (2) Prescribers must add documentation requirements to EMR/EHR templates for all pediatric antipsychotic prescriptions including: comprehensive psychiatric/developmental evaluation, chart notes, baseline weight/BMI, blood pressure, fasting glucose or A1c, lipid panel, and AIMS scoring. (3) Prior authorization request forms must be updated to capture: FDA-approved indication verification, dose justification per labeling or compendia, specialist type (for patients under 14: pediatric neurologist, child/adolescent psychiatrist, or child development pediatrician; for ages 14+: add general psychiatrist option), and baseline metabolic monitoring evidence. (4) Train billing and prior auth staff on new pediatric guidelines and therapeutic duplication rules. (5) Verify contractor/managed care organizations have updated their parallel guidelines for MA managed care delivery systems. Failure to obtain prior authorization will result in claim denials for affected antipsychotic prescriptions.